Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

Pfizer has reported promising mid-stage trial results for berobenatide, an experimental weight-loss and diabetes medication that could become the world's first once-a-month GLP-1 injection if approved ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Pfizer hasn't yet tapped into the highly lucrative market of diabetes drugs that have been increasingly used for weight loss purposes. Searching for a weight-loss drug but don't like the idea of an ...